Skip to main content

Parliamentary debates and questions

S5W-00536: Kezia Dugdale (Lothian)

Scottish Labour

Date lodged: 6 June 2016

To ask the Scottish Government what its policy is on pre-exposure prophylaxis (PrEP) and whether it will make it available on the NHS.

Answered by: Aileen Campbell 16 June 2016

Pre-exposure prophylaxis (PrEP) for HIV involves HIV-negative people taking antiretroviral drugs to reduce the risk of acquiring HIV. The Scottish Medicines Consortium (SMC) provides advice to NHS boards in Scotland about newly licensed medicines and new formulations and indications of established products following submissions from pharmaceutical companies. The SMC will only consider new treatments within their licensed indication once they have been granted a marketing authorisation (licence). Manufacturers can seek a marketing authorisation for new drugs and indications from either the European Medicines Agency or Medicines and Healthcare Products Regulatory Agency. To date, no manufacturer has received a marketing authorisation and made a submission to the SMC. The Scottish Government will continue to monitor this situation and in the meantime, the sexual health and blood borne virus clinical leads network have established a short life working group to consider a range of issues associated with PrEP in the current context.